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OBJECTIVES The purpose of this study was to evaluate the feasibility and safety of intracoronary
hyperoxemic reperfusion after primary angioplasty for acute myocardial infarction (MI).
BACKGROUND Hyperoxemic therapy with aqueous oxygen (AO) attenuates reperfusion injury and preserves
left ventricular (LV) function in experimental models of MI.
METHODS In a multi-center study of patients with acute MI undergoing primary angioplasty (PTCA),
hyperoxemic blood (pO2: 600 to 800 mm Hg) was infused into the infarct-related artery for
60 to 90 min after intervention. The primary end points were clinical, electrical and
hemodynamic stability during hyperoxemic reperfusion and in-hospital major adverse cardiac
events. Global and regional LV function was evaluated by serial echocardiography after
PTCA, after AO infusion, at 24 h and at one and three months.
RESULTS Twenty-nine patients were enrolled (mean age: 58.9  12.6 years). Hyperoxemic reperfusion
was performed successfully in all cases (mean infusion time: 80.8  18.2 min; mean coronary
perfusate pO2: 631  235 mm Hg). There were no adverse events during hyperoxemic
reperfusion or the in-hospital period. Compared with baseline, a significant improvement in
global wall motion score index was observed at 24 h (1.68 0.24 vs. 1.48 0.24, p 0.001)
with a trend toward an increase in ejection fraction (48.6  7.3% vs. 51.8  6.8%, p  0.08).
Progressive improvement in LV function was observed at one and three months, primarily
due to recovery of infarct zone function.
CONCLUSIONS Intracoronary hyperoxemic reperfusion is safe and well tolerated after primary PTCA. These
preliminary data support the need for a randomized controlled trial to determine if
hyperoxemic reperfusion enhances myocardial salvage or improves long-term
outcome. (J Am Coll Cardiol 2002;39:387–92) © 2002 by the American College of
Cardiology
Left ventricular (LV) function is the most important deter-
minant of survival after acute myocardial infarction (AMI)
(1–4). Early and sustained restoration of flow in the
infarct-related artery salvages jeopardized myocardium, re-
duces infarct size and preserves LV function (2,5–8). It is
not uncommon, however, to observe a relatively modest
improvement in ventricular function despite successful re-
canalization of the infarct vessel. It is clear that the presence
of normal angiographic epicardial flow does not guarantee
adequate myocardial perfusion (9). Failure to re-establish
myocardial flow may be due to reperfusion injury, ischemia-
induced microvascular damage or distal embolization from
the lesion site (10,11). Regardless of the mechanism, failure
to restore effective myocardial perfusion is associated with
poor recovery of LV function (9,12).
Although oxygen free radicals are generated on normox-
emic reperfusion, paradoxically, reperfusion injury can be
attenuated by treatment with high oxygen tensions (13,14).
Experimental data suggest this effect is mediated, in part, by
antagonism of lipid peroxidation (15), inhibition of post-
capillary venule leukocyte plugging (16) and increasing
functional capillary density (13). Aqueous oxygen (AO) is a
recently discovered liquid phase combination of water and
medical grade oxygen that can be mixed with blood at
ambient pressure to correct hypoxemia or produce hyperox-
emia with small amounts of carrier solution (17). Regional
organ or tissue perfusion is achieved using a blood loop
(TherOx Inc., Irvine, California), permitting precise control
of the pO2 when AO is mixed with arterial blood in the
circuit. In experimental models of MI, hyperoxemic reper-
fusion with AO has been demonstrated to attenuate micro-
vascular injury and preserve LV function (17).
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The purpose of this study was to evaluate the safety and
feasibility of performing intracoronary hyperoxemic reper-
fusion using AO after primary angioplasty for AMI.
METHODS
Patient population. From April to December 1999, 29
patients with AMI undergoing primary angioplasty were
enrolled in this prospective, multi-center study. All patients
presented within 24 h from symptom onset and had chest
pain lasting 30 min duration with ST-segment elevation
1 mm in two limb leads or2 mm in the precordial leads.
Exclusion criteria were: cardiogenic shock (blood pressure
[BP] 80 mm Hg for 30 min not responsive to fluids or
systolic BP 100 mm Hg with vasopressors), requirement
for an intra-aortic balloon pump before or during coronary
angioplasty, significant left main disease (50% diameter
stenosis), use of a non-balloon or stent device, Thrombolysis
In Myocardial Infarction (TIMI) flow grade 2 after
intervention, coronary artery bypass surgery within one
month, severe cardiac valvular stenosis or insufficiency,
pericardial disease, non-ischemic cardiomyopathy and preg-
nant women. Written informed consent was obtained from
each patient before the procedure. The local institutional
review board at each center approved the trial.
Catheterization. Before catheterization all patients re-
ceived low flow nasal oxygen, aspirin 300 mg orally and
heparin 5,000 U intravenously. Diagnostic coronary arte-
riography was performed via the femoral approach accord-
ing to the Judkins technique, and arteries were visualized in
multiple projections. The infarct-related artery was identi-
fied by localization of the electrocardiographic findings, site
of the coronary occlusion or hemodynamically significant
lesion and by analysis of the wall motion defect by ventricu-
lography. Coronary intervention was performed using 7F or
8F guide catheters and standard guidewires and balloon
catheters. Heparin was given to maintain the activated
clotting time greater than 250 s. Stent deployment and use
of glycoprotein receptor antagonists were permitted at the
physician’s discretion.
AO system. Hyperoxemic reperfusion was commenced
after the coronary intervention was completed. Before the
procedure, AO solution was prepared on site in a custom
fluid vessel (TherOx, Inc., Irvine, California) to a concen-
tration of 1 ml O2/ml Lactated Ringer’s solution. Aqueous
oxygen was transferred into the AO system circuit via a
custom syringe pump (TherOx, Inc., Irvine, California). In
phase I of the study (nine patients), blood for the AO
system circuit was withdrawn from a 4F or 6F sheath in the
contralateral femoral artery or radial artery into 1/8-inch
(internal diameter) PVC tubing (Baxter Healthcare Corp.,
Irvine, California) via a two-roller peristaltic tubing pump
(Pemco, Inc., Cleveland, Ohio). Blood was delivered at 100
ml/min to a polycarbonate-mixing chamber (TherOx, Inc.,
Irvine, California) where it was directly mixed with AO.
The AO flow rate was 1.5 to 3.0 ml/min (mean: 2.9  0.5
ml/min) to achieve a blood pO2 of 600 to 800 mm Hg in
the mixing chamber (verified by blood-gas analysis). Hy-
peroxemic blood was then delivered to the patient via a
3/32-inch (internal diameter) PVC tubing (Qosina, Edge-
wood, New York) connected to a 7F Vector guide catheter
(Medtronic, Inc., Minneapolis, Minnesota). The priming
volume of the AO system circuit was 60 ml. The phase I
treatment time was 60 min.
In phase IA of the study, the AO system circuit was
nearly identical, with the following exceptions: 1) a 4F
coronary infusion catheter (Tracker-38, Target Therapeu-
tics, Fremont, California) was subselectively positioned in
the infarct-related artery; 2) due to the subselective nature of
the infusion, the blood flow rate of the peristaltic pump was
decreased to 75 ml/min; and 3) the phase IA treatment time
was 90 min.
During hyperoxemic reperfusion, femoral and pulmonary
arterial pressures and saturations, systemic pO2, electrocar-
diograms and echocardiograms were obtained every 15 min.
Selective infarct vessel angiography was repeated after com-
pletion of the intracoronary infusion. Patients were moni-
tored in the intensive care unit after the procedure and were
treated according to local management guidelines.
Angiographic analysis. Quantitative angiography was per-
formed using an automated edge detection system (CAAS
II, Pie Medical, Maastricht, the Netherlands). Calibration
was based on the dimension of a contrast-filled catheter.
Multi-vessel coronary disease was defined as 50% stenosis
in one or more vessels remote from the infarct artery.
Patency of the infarct-related artery was classified according
to the TIMI criteria (18).
Echocardiographic analysis. Two-dimensional echocardi-
ography was performed after primary angioplasty, during
and immediately after the AO infusion, at 24 h, and at one
and three months. During the AO infusion patients were
supine; for all other studies, patients were placed in the left
lateral decubitus position. Echocardiographic imaging was
performed with commercially available equipment, and
studies were recorded on videotape. Calculations for global
and regional wall motion were performed both on- and
off-line (Kodak ImageVue Compact Workstation, Allen-
dale, New Jersey). Parasternal long-axis, short-axis, four-
chamber and two-chamber views were included for analysis.
Post-treatment studies were analyzed in random sequence
by two observers blinded to clinical details and outcome. In
the event of conflicting wall motion scores, studies were
Abbreviations and Acronyms
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reread until a consensus was reached between observers, or
a third observer was asked to adjudicate the findings.
The LV wall was divided into 16 segments and regional
wall motion for each segment was scored according to the
recommendation of the American Society of Echocardiog-
raphy (19). Segments were graded as 1  normal (or
hyperkinetic), 2  hypokinetic, 3  akinetic and 4 
dyskinetic. The LV ejection fraction (EF) was estimated by
tracing the endocardial contour in end-diastole and end-
systole according to biplane Simpson’s rule. Global and
regional wall motion score indexes (WMSI) were derived by
the formula: WMSI  sum of the segment scores/number
of segments scored.
Study end points. The primary end points were clinical
(chest pain, ST elevation, abnormal flow in the infarct-
related artery), electrical (heart block, ventricular arrhyth-
mia) or hemodynamic (changes in heart rate, systemic or
pulmonary artery pressures) instability during the AO infu-
sion and in-hospital clinical events including death, bleed-
ing, recurrent ischemia, target vessel revascularization and
new or progressive heart failure. Major bleeding was defined
as intra-cranial hemorrhage or the need for blood transfu-
sion. Predefined secondary end points were global and
regional LV function at 24 h, one month and three months.
Clinical follow-up was obtained in all patients at 30 days.
Statistical analysis. Statistical analysis was performed us-
ing SAS software (version 6.12, Cary, North Carolina).
Results are expressed as mean SD or percentage. Changes
in hemodynamic parameters, WMSI and EF were evaluated
using repeated measures analysis of variance. If significance
was found, post-hoc analysis was performed using Tukey’s
highest significant difference test. A p value 0.05 was
considered statistically significant.
RESULTS
Clinical and angiographic data. Twenty-nine patients (24
men, 5 women, mean age: 58.9  12.6 years) were enrolled
in this study (Table 1). Nineteen patients (65%) had
infarction of the anterior wall. The mean time to reperfu-
sion was 5.4  3.8 h from symptom onset. Stenting was
performed in almost all patients (93%) and most received a
glycoprotein receptor antagonist (76%). The peak creatine
kinase level and mean hospital stay were 3,264 2,868 IU/l
and 5.9  2.9 days, respectively.
After percutaneous transluminal coronary angioplasty
(PTCA) or stenting, 26 patients (90%) had a successful
angiographic result with TIMI grade 3 flow. The mean
diameter stenosis after intervention was 4.9  6.1%. One
patient had an improvement in epicardial flow (TIMI flow
grade 2 to 3) after the AO infusion (Fig. 1).
Hyperoxemic reperfusion. Hyperoxemic blood was in-
fused successfully in all patients (mean infusion time:
80.8  18.2 min). The mean loop flow and pO2 of the
coronary perfusate were 82  13 ml/min and 631 
235 mm Hg, respectively. Despite the high pO2 of the
coronary perfusate, there was only a modest increase in
mean systemic arterial pO2 from baseline levels (150 
74 mm Hg vs. 170  83 mm Hg, p  0.01) (Table 2).
Primary and secondary end points. Hyperoxemic reper-
fusion was well tolerated in all patients. No clinical, elec-
trical or hemodynamic instability was observed during the
AO infusion (Table 2). There was a small but significant
decrease in mean pulmonary wedge pressure at the end of
the infusion compared with after angioplasty (21  9 mm
Hg vs. 16  7 mm Hg, p  0.04) (Table 2). There were no
procedure-related complications.
During the in-hospital period, one patient developed
congestive heart failure, which was treated with conven-
tional therapy, and one patient required a blood transfusion
because of bleeding at the femoral access site. There were no
other adverse events during the hospitalization period.
At 30-day clinical follow-up there were no deaths, nor
did any patients experience reinfarction, recurrent ischemia
or need repeat target vessel revascularization.
LV function analysis. GLOBAL LV FUNCTION. Baseline and
follow-up echocardiograms were performed in 28 (96%)
patients (one patient was excluded because of technical
difficulty with imaging). The EF and global WMSI imme-
diately after angioplasty were: 48.6 7.3% and 1.68 0.24,
Table 1. Baseline Clinical and Angiographic Characteristics
(n  29)
n (%)





Current smoker 15 (52%)
History MI 6 (21%)
Previous PTCA 4 (14%)
Previous CABG 0 (0%)
Rescue PTCA 7 (24%)
Mean time to reperfusion from symptom
onset (h)
5.4  3.8















Mean infarct vessel stenosis (%) 96.2  6.7
Stent 27 (93%)
Glycoprotein IIb/IIIa antagonist 22 (76%)
CABG  coronary artery bypass grafting; LAD  left anterior descending coronary
artery; MI  myocardial infarction; PTCA  percutaneous transluminal coronary
angioplasty; RCA  right coronary artery; TIMI  Thrombolysis In Myocardial
Infaction.
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respectively. A significant improvement in WMSI was
demonstrated at 24 h (WMSI: 1.48  0.24, p  0.001)
with a trend toward an increase in EF (51.8  6.8%, p 
0.08) (Fig. 2 and 3). Progressive improvement in ventricular
function was demonstrated at one and three months com-
pared with baseline: WMSI one month: 1.39  0.24 (p 
0.001), EF one month: 54.4  6.6% (p  0.001), WMSI
three months: 1.34  0.26 (p  0.001) and EF three
months: 56.0  8.3% (p  0.001).
REGIONAL LV FUNCTION. The WMSI was analyzed ac-
cording to infarct and non-infarct zones. The WMSI of the
infarct zone was 2.18  0.32 after primary PTCA and
2.02  0.37 (p  NS) immediately after hyperoxemic
reperfusion (Fig. 4). At 24 h a significant improvement in
infarct zone function was observed (WMSI: 1.84  0.41,
p  0.001), with sustained improvement at one month
(WMSI: 1.68  0.44, p  0.001) and three months
(WMSI: 1.63  0.43, p  0.001) compared with baseline.
No significant change in WMSI was observed in the
non-infarct zone.
DISCUSSION
The primary purpose of this study was to evaluate the
feasibility and safety of performing hyperoxemic reperfusion
in patients undergoing primary angioplasty for AMI. The
main finding of the study was that hyperoxemic reperfusion
using AO after recanalization of the infarct vessel is safe and
well tolerated. Although this study was not designed to
evaluate the clinical efficacy of hyperoxemic reperfusion,
results of the LV analysis suggest this therapy may promote
healing and lead to early recovery of function in the infarct
zone.
Rationale for this study. Hyperbaric oxygen therapy has
been shown to reduce reperfusion injury and limit infarct
size in experimental models of AMI (20). This benefit has
been confirmed in clinical studies, with a reduction in
arrhythmia, improved ST-segment resolution and decrease
in creatine kinase release (21–23). However, using hyper-
baric oxygen chambers in the setting of AMI is not only
cumbersome but is limited by cost, access and concern about
pulmonary toxicity. In light of these issues, the introduction
of AO has been a major advance because this therapy can be
used to produce hyperoxemia on a regional basis.
Although the precise biochemical and cellular mecha-
nisms have yet to be fully elucidated, the effects of hyper-
baric oxygen appear to be mediated, in part, by an increase
in capillary density in post-ischemic tissue (13) and by a
reduction in leukocyte adherence in post-capillary venules
(16). More recently, hyperbaric oxygen therapy has been
Figure 1. Infarct vessel Thrombolysis In Myocardial Infarction (TIMI) flow grade: before coronary angioplasty (PTCA), after PTCA and after the aqueous
oxygen (AO) infusion.
Table 2. Hemodynamic Parameters and pO2 During the AO Infusion
Baseline 15 min 30 min 45 min 60 min 75 min 90 min
BP systolic 124.0  16.4 122.2  17.4 123.0  19.8 123.2  18.0 124.8  16.7 122.7  14.7 122.8  17.3
BP diastolic 80.5  11.2 78.4  10.9 78.2  11.1 80.5  9.7 79.3  9.3 80.5  10.0 80.7  11.9
Heart rate (beats/min) 78.4  11.3 71.5  11.3 71.5  12.8 71.1  13.4 73.8  10.6 72.1  15.4 73.2  14.9
PA systolic 36.2  12.7 31.5  12.4 31.6  9.0 31.2  10.2 31.4  9.4 31.0  12.3 31.3  10.3
PA diastolic 19.3  5.3 17.2  6.4 17.6  7.0 17.5  7.1 16.2  6.4 16.5  7.5 16.3  5.4
PCW 21.4  9.0 17.6  7.5 18.4  6.6 17.1  8.3 16.6  6.2 17.9  8.2 16.0  6.9*
Systemic pO2 149.4  73.6 170.0  83.0 174.5  72.4 174.0  84.6 174.9  79.8 166.9  59.7 166.7  78.6†
Loop pO2 631.8  235.7 684.9  187.8 725.2  196.1 719.9  177.3 728.8  186.7 746.1  206.7 751.4  188.4
*p  0.04 vs. baseline; †p  0.01 vs. baseline. All mesurements are mm Hg unless indicated.
AO  aqueous oxygen; BP  blood pressure; Loop pO2  pO2 of blood infused into the infarct–related artery via the distal portion of the aqueous oxygen system circuit;
PA  pulmonary artery pressure; PCW  pulmonary capillary wedge pressure.
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shown to impair cyclic guanosine monophosphate synthesis
in activated neutrophils, thereby inhibiting 2 integrin-
dependent adherence (24). Despite concern about hyperox-
emia increasing free radical production, biochemical data
have demonstrated that the converse is true with hyperbaric
oxygen enhancing a biochemical pathway that reduces
formation of lipid peroxide radicals (15).
Experimental studies using AO. The effect of AO hyper-
oxemic reperfusion was initially investigated in a canine
model of myocardial ischemia (17). Low coronary blood
flow in the circumflex artery was delivered with a roller
pump through the central lumen of a balloon occlusive
catheter. A significant decrease in LV function was observed
during low-flow hypoxemic and low-flow normoxemic per-
fusion, but this was prevented with hyperoxemic perfusion.
In a subsequent study, the proximal left anterior descending
or circumflex arteries of dogs were balloon occluded for 90
min. Hyperoxemic reperfusion with AO was associated with
a significant improvement in two-dimensional echocardiog-
raphy EF compared with controls (Spears JR, MD, unpub-
lished data, 1997). The improvement in EF was unchanged
30 min after termination of hyperoxemic perfusion. More
recent data show that animals treated with AO hyperoxemic
reperfusion have smaller infarct size with reduced myelo-
peroxidase levels, improved myocardial blood flow and
preservation of endothelial cell morphology in the ischemic
segment compared with animals undergoing normoxemic
reperfusion (Spears JR, MD, unpublished data, 1999).
These observations suggest that hyperoxemia may attenuate
reperfusion microvascular ischemia and, thereby, limit tissue
injury.
Recovery of LV function in previous studies. While the
importance of infarct vessel patency for late recovery of
ventricular function is well established (8), most studies have
shown little or no improvement between early and late EF
after reperfusion as a result of hyperkinesis in the non-
infarct zone. For this reason, the WMSI is a more accurate
method of assessing changes in global and regional LV
function after reperfusion because it negates the effect of
non-infarct zone hyperkinesis. Broderick et al. (25) used
WMSI to evaluate 50 patients undergoing successful reper-
fusion therapy, with serial echocardiograms performed early
(within 24 h) and late (mean: six days) after presentation.
Overall, there was an improvement in WMSI (1.73 to 1.43,
p  0.001) but no significant change in LV EF. In this
study we observed a trend toward improved EF 24 h after
reperfusion (46.8 vs. 51.8%, p  0.08) in addition to an
early improvement in global WMSI. Although our study
was not designed to assess the efficacy of hyperoxemic
reperfusion, the improvement in infarct zone WMSI early
after reperfusion was greater than expected from historic
controls. While it is tempting to speculate this benefit was
related to AO hyperoxemic reperfusion, this hypothesis
needs to be tested in a randomized controlled trial.
Study limitations. Two different methods were used in
this study to perform hyperoxemic reperfusion. After the
first nine patients, the loop system was modified, and
hyperoxemic blood was infused selectively into the infarct
vessel via an intracoronary infusion catheter (rather than
through the guide catheter) in order to optimize delivery of
hyperoxemic blood to the infarct bed. Although no signif-
Figure 4. Wall motion score index (WMSI) of infarct and non-infarct
zones at baseline and after hyperoxemic reperfusion with aqueous oxygen
(AO). Solid triangle  infarct zone; solid square  non-infarct zone. *p
 0.01 (vs. baseline); †p  0.01 (vs. 24 h).
Figure 2. Global left ventricular ejection fraction immediately after pri-
mary percutaneous transluminal coronary angioplasty (baseline) and after
hyperoxemic reperfusion with aqueous oxygen (AO). *p  0.08 (vs.
baseline); †p  0.001 (vs. baseline); ‡p  0.005 (vs. 24 h).
Figure 3. Global wall motion score index (WMSI) immediately after
primary percutaneous transluminal coronary angioplasty (baseline) and
after hyperoxemic reperfusion with aqueous oxygen (AO). *p  0.001 (vs.
baseline); †p  0.005 (vs. 24 h).
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icant difference in global or regional wall motion was
observed between the two delivery techniques, the small
number of patients studied limits this analysis. For the same
reason, we are unable to determine if hyperoxemic reperfu-
sion has different effects in patient subgroups, such as those
who received thrombolytic therapy or a glycoprotein recep-
tor inhibitor.
There are several potential limitations with the echocar-
diographic analysis. First, assessment of ventricular function
using the WMSI is semi-quantitative and requires optimal
echocardiographic imaging to visualize all myocardial seg-
ments. However, this technique is well validated and pro-
vides a more accurate assessment of ventricular function
than the EF alone. In this study, technically adequate
images were obtained in the majority of patients, and the
analysis was performed by two observers to minimize
variability in interpretation. Second, significant hyperkinesis
of the non-infarct zones was commonly observed during
and immediately after primary angioplasty, which may have
led to over-estimation of the baseline EF. In most cases,
however, this had resolved by 24 h, suggesting that hyperki-
nesis had minimal effect on calculation of EF beyond the
procedure itself. Myocardial contrast echocardiography was
not performed in this study, although it would have been
useful to further define the effects of AO on myocardial
perfusion.
Implications. This is the first clinical study evaluating AO
hyperoxemic reperfusion in AMI. This pilot study demon-
strated that intracoronary hyperoxemic reperfusion is safe
and well tolerated and may provide a new means to improve
myocardial salvage after primary angioplasty. These prelim-
inary data support the need for a randomized controlled trial
of hyperoxemic reperfusion to evaluate the effect of this
therapy on ventricular function and clinical outcome.
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